logo
It's a hot summer and that means blue-green algae is back, GRCA warns

It's a hot summer and that means blue-green algae is back, GRCA warns

Yahoo26-07-2025
The hot weather this summer means blue-green algae is starting to bloom in local waterways, the Grand River Conservation Authority says.
So far this summer, blue-green algae has been seen near the west side of Shand Dam at Belwood Lake reservoir.
In the past, the algae has also shown up in Conestogo Lake, Guelph Lake and Woolwich reservoirs, as well as at Snyder's Flats.
When an algal bloom starts to grow, "a noticeable green or brown scum will form on the surface of water bodies and the water look like green or bluish-green pea soup," the conservation authority says.
"Once blue-green algae are in full bloom, it may look like spilled 'paint' along the shoreline. A new blue-green algal bloom often smells like fresh cut grass, while an older bloom can smell like rotting garbage."
The algae grows thanks in part to nutrients from fields and lawns that end up in local waterways and reservoirs when it rains, the authority says.
People are reminded not to touch the algae as it can be harmful to people and pets.
As well as avoiding any contact with the blue-green algae, people shouldn't use water from a reservoir where the algae is found and should not eat fish from the water, either.
Assume it contains toxins: health unit
Wellington-Dufferin-Guelph Public Health notes on its website that blue-green algae, also called cyanobacteria, usually shows up in late summer or early fall and higher water temperatures help it grow.
"There's no way to tell by looking at a bloom whether it contains toxins or not. As a precaution, regard any blue-green algal bloom as potentially toxic," the health unit says.
People who do come in contact with blue-green algae may experience itchy or irritated eyes and skin, headaches, fever, diarrhea, stomach pain and nausea. If large amounts are ingested, there can be more serious effects such as liver damage.
The health unit also notes infants and children under the age of six are most at risk of developing health problems if exposed to the algae.
If someone does come into contact with blue-green algae, Wellington-Dufferin-Guelph Public Health says they should rinse off immediately with clean water and watch for symptoms. If symptoms show up, speak to a health-care provider.
People who spot blue-green algae where there are no posted signs are asked to report it to the Grand River Conservation Authority and or the Ministry of Environment, Conservation and Parks spill action centre.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ontario labour federation urges more worker protections as air quality concerns grow
Ontario labour federation urges more worker protections as air quality concerns grow

Yahoo

time2 hours ago

  • Yahoo

Ontario labour federation urges more worker protections as air quality concerns grow

An Ontario labour group says it is advocating for more robust worker protections amid growing health concerns over poor air quality as wildfire smoke blankets the province with increasing frequency. The Ontario Federation of Labour, which represents more than 55 unions across the province, says the push is part of a broader heat stress strategy looking at how climate change is impacting working conditions. Its president Laura Walton says provincial regulations outline winter temperature benchmarks to protect workers from the cold, but there are no such protections from the heat or poor air quality. She says the federation is working with the provincial New Democrats to introduce a motion to the legislature in November advocating for better worker protections amid increasing extreme weather events. Michael Lynk, professor emeritus of law at Western University and a former labour lawyer, says the more frequent air quality warnings should require unions to be more 'aggressive' in asserting workplace rights in the coming years. He says workers have the right to refuse work if they feel unsafe in extreme heat or smoke, which can send a powerful message to employers to re-examine working conditions. This report by The Canadian Press was first published Aug. 6, 2025. Natasha Baldin, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer
Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer

Associated Press

time8 hours ago

  • Associated Press

Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer

MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy. The approval is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine.1,2 In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant and clinically meaningful 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi plus gemcitabine and cisplatin arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm.2 Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus the comparator arm (based on OS HR of 0.75; 95% CI 0.59-0.93; p=0.011). Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm.2 Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. The most common adverse events (any Grade, occurring in ≥10% of patients) for the Imfinzi plus chemotherapy arm were nausea (53.6%), fatigue (51.5%), neutropenia (40.4%), anemia (38.7%), constipation (38.7%), decreased appetite (26.6%), rash (20.9%), pyrexia (20.8%), diarrhea (20.6%), abdominal pain (20.2%), vomiting (19.2%), blood creatine increased (18.5%), thrombocytopenia (17.2%), pruritus (15.1%), hypothyroidism (12.6%), neuropathy peripheral (12.5%), leukopenia (10.9%), and aspartate aminotransferase increased (10.4%).1 'Health Canada's approval of this durvalumab-based perioperative regimen represents a major advance for Canadians with muscle invasive bladder cancer, where nearly half will relapse despite curative treatment,' says Dr. Srikala Sridhar, Professor of Medicine at the University of Toronto, Genitourinary Medical Oncologist at the Princess Margaret Cancer Centre and NIAGARA trial investigator. 'Findings from the NIAGARA trial showed that this new regimen reduces risk of recurrence and significantly improves survival – which may offer new hope and potential to transform care in this setting.' 'The high rate of recurrence associated with muscle invasive bladder cancer is an ongoing challenge and source of concern for physicians and patients,' says Dr. Normand Blais, Medical Oncologist at the Centre hospitalier de l'Université de Montréal. 'The Health Canada approval based on results from the NIAGARA trial may now offer us the opportunity to increase the chance of better patient outcomes and long-term survival by the use of immunotherapy in this setting, which is very good news for patients and their families.' Bladder cancer is the 5th most common cancer in Canada, with more than 13,000 patients diagnosed each year.3 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract. Bladder cancer is considered muscle invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases.4 In MIBC, approximately 50% of patients who undergo bladder removal surgery experience disease recurrence.5 Treatment options that prevent disease recurrence after surgery are critically needed in this curative-intent setting. 'This decision by Health Canada represents an important step forward for all Canadians affected by muscle invasive bladder cancer,' says Michelle Colero, Executive Director, Bladder Cancer Canada. 'For many patients and families, the fear of recurrence after surgery has been overwhelming. This new treatment option may offer renewed hope for longer, healthier lives.' About NIAGARA2 NIAGARA is a randomized, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 patients were randomized to receive four cycles of Imfinzi plus neoadjuvant chemotherapy prior to cystectomy followed by eight cycles of Imfinzi monotherapy, or neoadjuvant chemotherapy alone prior to cystectomy with no further treatment after surgery. NIAGARA is the largest global Phase III trial in this setting to date. The trial is being conducted at 192 centres in 22 countries across North America (including Canada), South America, Europe, Australia and Asia. Its dual primary endpoints are EFS and pathologic complete response at the time of cystectomy. Key secondary endpoints are OS and safety. About Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at Imfinzi® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. References: SOURCE AstraZeneca Canada Inc.

New book, ‘Whispers from the Shadow,' spotlights suicide's silent struggle: A psychologist's battle with his own shadow
New book, ‘Whispers from the Shadow,' spotlights suicide's silent struggle: A psychologist's battle with his own shadow

Associated Press

time10 hours ago

  • Associated Press

New book, ‘Whispers from the Shadow,' spotlights suicide's silent struggle: A psychologist's battle with his own shadow

- 'Whispers from the Shadow: Confronting the Call of Suicide' by Dr. Jacques A. Frigault, blends memoir, facts, philosophical perspectives and a powerful call to action during suicide prevention month in September - TORONTO, Ontario, Aug. 6, 2025 (SEND2PRESS NEWSWIRE) — What if the very voice that drove you to save others was the same one urging you toward the edge? Icy Peaks Publishing is proud to announce the release of 'Whispers from the Shadow: Confronting the Call of Suicide' (ISBN: 978-1069171009) by Dr. Jacques A. Frigault. Dr. Frigault holds a doctorate in psychology and breaks decades of silence to share a most personal and haunting story – his own. His work is especially timely with September marking National Suicide Prevention Month and World Suicide Prevention Day observed on September 10. For more than 50 years, Dr. Frigault guided others out of the darkness. He helped them to face personal mental health struggles and to overcome thoughts of suicide. In this book, he reveals the painful truth behind his life's work: he, too, was battling an inner voice – born from the devastating loss of his older brother to suicide at a young age — that beckoned him toward the same fate. This deeply moving and eye-opening book is more than a memoir. It's a testament to the human spirit's ability to endure and rise. Dr. Frigault takes readers on a journey through grief, resilience and renewal. He offers powerful insight into suicide's emotional, historical and philosophical roots. He draws from personal experience and clinical expertise, and dispels harmful myths, illuminates warning signs and encourages life-saving dialogue. As suicide rates continue to climb (53,000+ lives were lost to suicide in North America in 2023), Dr. Frigault's message is more urgent than ever. He is available for interviews to discuss his book, suicide prevention efforts, and to share how anyone can better equip themselves to recognize and respond to silent suffering. Icy Peaks Publishing invites media outlets to join in raising awareness by featuring 'Whispers from the Shadow' in upcoming stories. Review copies are available upon request, and 'Whispers from the Shadow' is now available in paperback and eBook formats through Amazon. Learn more about the book at: About the Author Dr. Jacques A. Frigault is a Doctor of Psychology and author. With a career spanning over 50 years, he has dedicated his life to advancing psychological care and well-being. As an author, he has published 12 books in French and several research papers, contributing valuable insights to the fields of psychology, each reflecting his profound understanding of the human mind and spirit. Dr. Frigault was born and continues to reside in Tracadie, New Brunswick, Canada. About Icy Peaks Publishing Icy Peaks Publishing is an independent publishing house with a mission to bring insightful French literature to the English-speaking world — and vice versa. It specializes in translating and publishing books in English and French and connects readers with compelling stories that might otherwise remain out of reach. Learn more at: FOLLOW ON SOCIAL: Instagram: @icypeakspublishing NEWS SOURCE: Icy Peaks Publishing Keywords: Books and Publishing, Icy Peaks Publishing, suicide prevention month, Dr. Jacques A. Frigault, nonfiction, memoir, self-help, Whispers from the Shadow: Confronting the Call of Suicide, ISBN 9781069171009, TORONTO, Ontario This press release was issued on behalf of the news source (Icy Peaks Publishing) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P128280 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store